Literature DB >> 25030430

Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis.

A L Zignego1, G L Wojcik2, P Cacoub3, M Visentini4, M Casato4, A Mangia5, R Latanich6, E D Charles7, L Gragnani1, B Terrier8, V Piazzola5, L B Dustin7, S I Khakoo9, M P Busch10, G M Lauer11, A Y Kim11, L Alric12, D L Thomas6, P Duggal2.   

Abstract

The host genetic basis of mixed cryoglobulin vasculitis is not well understood and has not been studied in large cohorts. A genome-wide association study was conducted among 356 hepatitis C virus (HCV) RNA-positive individuals with cryoglobulin-related vasculitis and 447 ethnically matched, HCV RNA-positive controls. All cases had both serum cryoglobulins and a vasculitis syndrome. A total of 899 641 markers from the Illumina HumanOmni1-Quad chip were analyzed using logistic regression adjusted for sex, as well as genetically determined ancestry. Replication of select single-nucleotide polymorphisms (SNPs) was conducted using 91 cases and 180 controls, adjusting for sex and country of origin. The most significant associations were identified on chromosome 6 near the NOTCH4 and MHC class II genes. A genome-wide significant association was detected on chromosome 6 at SNP rs9461776 (odds ratio=2.16, P=1.16E-07) between HLA-DRB1 and DQA1: this association was further replicated in additional independent samples (meta-analysis P=7.1 × 10(-9)). A genome-wide significant association with cryoglobulin-related vasculitis was identified with SNPs near NOTCH4 and MHC Class II genes. The two regions are correlated and it is difficult to disentangle which gene is responsible for the association with mixed cryoglobulinemia vasculitis in this extended major histocompatibility complex region.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25030430      PMCID: PMC4208981          DOI: 10.1038/gene.2014.41

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  40 in total

Review 1.  Cryoglobulinemic vasculitis.

Authors:  P Lamprecht; A Gause; W L Gross
Journal:  Arthritis Rheum       Date:  1999-12

2.  A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.

Authors:  S De Vita; L Quartuccio; M Isola; C Mazzaro; P Scaini; M Lenzi; M Campanini; C Naclerio; A Tavoni; M Pietrogrande; C Ferri; M T Mascia; P Masolini; A Zabotti; M Maset; D Roccatello; A L Zignego; P Pioltelli; A Gabrielli; D Filippini; O Perrella; S Migliaresi; M Galli; S Bombardieri; G Monti
Journal:  Arthritis Rheum       Date:  2012-03

Review 3.  Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.

Authors:  Franco Dammacco; Domenico Sansonno
Journal:  N Engl J Med       Date:  2013-09-12       Impact factor: 91.245

Review 4.  Cryoglobulinemia vasculitis: an update.

Authors:  Benjamin Terrier; Patrice Cacoub
Journal:  Curr Opin Rheumatol       Date:  2013-01       Impact factor: 5.006

Review 5.  Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.

Authors:  Maurizio Pietrogrande; Salvatore De Vita; Anna Linda Zignego; Pietro Pioltelli; Domenico Sansonno; Salvatore Sollima; Fabiola Atzeni; Francesco Saccardo; Luca Quartuccio; Savino Bruno; Raffaele Bruno; Mauro Campanini; Marco Candela; Laura Castelnovo; Armando Gabrielli; Giovan Battista Gaeta; Piero Marson; Maria Teresa Mascia; Cesare Mazzaro; Francesco Mazzotta; Pierluigi Meroni; Carlomaurizio Montecucco; Elena Ossi; Felice Piccinino; Daniele Prati; Massimo Puoti; Piersandro Riboldi; Agostino Riva; Dario Roccatello; Evangelista Sagnelli; Patrizia Scaini; Salvatore Scarpato; Renato Sinico; Gloria Taliani; Antonio Tavoni; Eleonora Bonacci; Piero Renoldi; Davide Filippini; Piercarlo Sarzi-Puttini; Clodoveo Ferri; Giuseppe Monti; Massimo Galli
Journal:  Autoimmun Rev       Date:  2011-02-15       Impact factor: 9.754

Review 6.  The hepatitis C virus infection as a systemic disease.

Authors:  Anna Linda Zignego; Laura Gragnani; Carlo Giannini; Giacomo Laffi
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

Review 7.  Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.

Authors:  Khayriyyah Mohd Hanafiah; Justina Groeger; Abraham D Flaxman; Steven T Wiersma
Journal:  Hepatology       Date:  2013-02-04       Impact factor: 17.425

8.  Fast and accurate genotype imputation in genome-wide association studies through pre-phasing.

Authors:  Bryan Howie; Christian Fuchsberger; Matthew Stephens; Jonathan Marchini; Gonçalo R Abecasis
Journal:  Nat Genet       Date:  2012-07-22       Impact factor: 38.330

9.  Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts.

Authors:  Priya Duggal; Chloe L Thio; Genevieve L Wojcik; James J Goedert; Alessandra Mangia; Rachel Latanich; Arthur Y Kim; Georg M Lauer; Raymond T Chung; Marion G Peters; Gregory D Kirk; Shruti H Mehta; Andrea L Cox; Salim I Khakoo; Laurent Alric; Matthew E Cramp; Sharyne M Donfield; Brian R Edlin; Leslie H Tobler; Michael P Busch; Graeme Alexander; Hugo R Rosen; Xiaojiang Gao; Mohamed Abdel-Hamid; Richard Apps; Mary Carrington; David L Thomas
Journal:  Ann Intern Med       Date:  2013-02-19       Impact factor: 25.391

Review 10.  HCV and lymphoproliferation.

Authors:  Anna Linda Zignego; Carlo Giannini; Laura Gragnani
Journal:  Clin Dev Immunol       Date:  2012-07-19
View more
  18 in total

1.  Association of Hepatitis C Virus Infection with Proteinuria and Glomerular Filtration Rate.

Authors:  Nargiza Kurbanova; Rehan Qayyum
Journal:  Clin Transl Sci       Date:  2015-08-14       Impact factor: 4.689

Review 2.  De novo autoimmune hepatitis in liver transplant: State-of-the-art review.

Authors:  Ranka Vukotic; Giovanni Vitale; Antonia D'Errico-Grigioni; Luigi Muratori; Pietro Andreone
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

Review 3.  Extrahepatic manifestations of chronic hepatitis C virus infection.

Authors:  Patrice Cacoub; Cloe Comarmond; Fanny Domont; Léa Savey; Anne C Desbois; David Saadoun
Journal:  Ther Adv Infect Dis       Date:  2016-02

4.  Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis.

Authors:  Stefania Colantuono; Milica Mitrevski; Baoran Yang; Julia Tola; Maurizio Carlesimo; Giuseppe M De Sanctis; Massimo Fiorilli; Milvia Casato; Marcella Visentini
Journal:  Clin Rheumatol       Date:  2017-01-22       Impact factor: 2.980

Review 5.  Innate and Adaptive Immune Responses in Chronic HCV Infection.

Authors:  Lynn B Dustin
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

Review 6.  The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review.

Authors:  Franco Dammacco; Vito Racanelli; Sabino Russi; Domenico Sansonno
Journal:  Clin Exp Med       Date:  2016-03-02       Impact factor: 3.984

Review 7.  Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?

Authors:  Chalermrat Bunchorntavakul; Robert Mitrani; K Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2017-12-07

Review 8.  Vasculitic syndromes in hepatitis C virus: A review.

Authors:  Gaafar Ragab; Mohamed A Hussein
Journal:  J Adv Res       Date:  2016-12-02       Impact factor: 10.479

Review 9.  New insights into HCV-related rheumatologic disorders: A review.

Authors:  Patrice Cacoub; Cloé Comarmond
Journal:  J Adv Res       Date:  2016-07-25       Impact factor: 10.479

Review 10.  Hepatitis C Therapy in Renal Patients: Who, How, When?

Authors:  Corinne Isnard Bagnis; Patrice Cacoub
Journal:  Infect Dis Ther       Date:  2016-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.